RSA® Conference Announces Jimmy Wales, Founder of Wikipedia as Closing Keynote Speaker at RSA® Conference Europe 2012 in October
General Registration is now open
RSA® Conference, the world’s leading information security conference group, today announced that Jimmy Wales, best known as the Founder of Wikipedia, is confirmed as the Closing Keynote Speaker at the 13th annual RSA Conference Europe . The Conference takes place from 9th -11th October 2012, at the Hilton London Metropole Hotel, U.K.
Mr. Wales is an Internet entrepreneur, wiki pioneer, and technology visionary, who is best known as the founder of Wikipedia, the international collaborative free content encyclopedia on the Internet that is the 5th most visited Web Site worldwide. One of The Guardian's “Open 20: fighters for Internet Freedom" the RSA Conference Europe audience will have the unique opportunity to hear a personal and inspirational message from one of the Internet’s true heroes.
Mr. Wales is also the founder of the Wikimedia Foundation, a non-profit charitable organisation dedicated to encouraging the growth, development and distribution of free, multilingual content, and to providing the full content of these wiki-based projects to the public free of charge. He also co-founded, the for-profit company Wikia, Inc., a wiki farm – a collection of individual wikis on different subjects, all hosted on the same website. Mr. Wales received his bachelor’s degree in finance from Auburn University and started with the Ph.D. finance program at the University of Alabama, where he left with a Master’s. He is also a Fellow of the Berkman Center for Internet & Society at Harvard Law School.
Sandra Toms LaPedis, General Manager of RSA Conference, commented: ”RSA Conference Europe is proud to welcome Wikipedia founder Jimmy Wales as this year's Closing Keynote Speaker. As a vocal supporter of free and open access to information on the web, our delegates will be extremely interested to hear Jimmy's thoughts on these issues and how they conflict or compliment developments in private and public sector IT security.”
General registration for RSA Conference Europe 2012 is now open, providing Delegates with a £225 discount off the standard registration fee if they sign up before 10th August. Delegates have access to all keynote sessions, all track sessions, discussion groups, all activities in Crypto Commons (the hub of RSA Conference Europe), Conference Bag and Presentations online.
Full details about registration and deadlines for special discounts are available at http://www.rsaconference.com/events/2012/europe/registration.htm
To find out more information regarding RSA Conference Europe 2012, please visit the event website at http://www.rsaconference.com/events/2012/europe/index.htm .
About RSA Conference
RSA Conference helps drive the global information security agenda with annual events in the U.S., Europe, and China. Throughout its 21-year history, RSA Conference consistently attracts the best and brightest in the field, creating opportunities to learn about information security’s most important issues through face-to-face and online interactions with peers, luminaries and emerging and established companies. As information security professionals work to stay ahead of ever-changing security threats and trends, they turn to RSA Conference for a 360-degree view of the industry. RSA Conference seeks to arm participants with the knowledge they need to remain at the forefront of the information security business. More information on events, online programming and the most up-to-date news pertaining to the information security industry can be found at www.rsaconference.com .
No. No. No.
RSA and RSA Conference logo are either registered trademarks or trademarks of EMC Corporation in the United States and/or other countries. All other marks are trademarks of their respective companies.
Contact:
Media Contact:
Andi Lustak
+44 20 81239946
andi.lustak@gmail.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom